Table of Contents
What changed
Revenue rose only 2.8% to NZ$318.1m, but earnings stepped up materially. EBITDA doubled to NZ$61.5m (HY23: NZ$30.5m), PBT rose 166.7% to NZ$48.8m, and NPAT attributable to shareholders rose to NZ$28.1m from NZ$3.9m. The swing is almost entirely a segment-mix story: Horticulture flipped from a NZ$2.1m loss to a NZ$22.3m profit on revenue up roughly 10%, while Global Proteins' segment profit slipped modestly to NZ$28.1m (HY23: NZ$30.3m) on lower revenue. Logistics improved to NZ$2.9m on higher volumes, and the "Other" segment loss narrowed.
Cash quality was mixed. Operating cash flow was still slightly negative at -NZ$2.6m, but materially less so than the -NZ$23.9m in HY23. Capex jumped nearly 9x to NZ$44.5m (14.0% of revenue vs 1.6% in HY23), driving pre-lease free cash flow to -NZ$47.1m. Gross borrowings rose 80% to NZ$121.8m and estimated net debt climbed to NZ$81.9m from NZ$29.8m, pushing net debt/EBITDA to 1.33x from 0.98x.
What matters
- Horticulture recovery is the whole story. The NZ$24.4m year-on-year swing in Horticulture segment result exceeds the NZ$30.5m group PBT increment when netted against softer Global Proteins. This is a cyclical, weather-sensitive recovery off a cyclone-affected HY23 base, not a structural step-up.
- Leverage direction has reversed. Net debt nearly tripled and leverage moved from under 1x to 1.33x EBITDA, reflecting a deliberate capex step-up rather than working-capital blowout. Whether the capex translates into durable earnings capacity is the key unresolved question.
- Underlying vs reported gap. Management points to underlying NPAT attributable of NZ$28.5m (up 97%) against reported NPAT of NZ$38.1m at the group level, versus NZ$28.1m attributable to shareholders. The release flags underlying figures but the supplied excerpt does not provide a reconciliation, so the quality of the "underlying" number cannot be independently verified here.
Expectations
No quantified FY24 guidance or forward-work target was provided in the supplied excerpts. Seasonality context works against simple annualisation: HY23 was 54.7% of FY23 revenue and 56.8% of FY23 EBITDA, so Scales is first-half weighted, particularly on earnings. Annualising HY24 revenue to NZ$636.2m (12.5% above FY23) would overstate the likely full-year outcome given this shape. On EBITDA, the HY24 figure of NZ$61.5m alone is already 14.5% above the full FY23 EBITDA of NZ$53.7m, implying FY24 EBITDA well ahead of FY23 even on a soft second half. The release does not support a more precise FY24 conclusion.
Quality of result
The earnings tax gate is clean: effective tax rate was broadly stable at about 22% in both periods, so the NPAT jump is genuine operating leverage rather than a below-the-line tax benefit. The gap between continuing-operations profit (NZ$38.1m) and attributable NPAT (NZ$28.1m) reflects minority interest rather than a discontinued-operation distortion.
Against that, three quality caveats stand out. First, the result is cyclical recovery — Horticulture moved from a loss to a healthy margin on only modest volume uplift, so the base effect is large. Second, operating cash conversion remains poor in seasonal terms (OCF/EBITDA of -4.2%), and the full-year cash shape last year relied heavily on a very strong second half (HY23 OCF was -NZ$23.9m on a full-year NZ$64.7m). Third, a NZ$47.1m pre-lease free cash outflow, funded by borrowings, means the earnings improvement has not yet shown up in the cash account; cash was only NZ$2.1m higher year on year despite the reported profit swing.
Unresolved
- What drove the nine-fold capex step-up, and what return on capital does management expect on it?
- What is the bridge between underlying NPAT attributable of NZ$28.5m and reported NPAT of NZ$38.1m, and how much of HY24 benefits from one-off or fair-value items?
- How much of the Horticulture recovery reflects price/mix versus a simple volume rebound from Cyclone Gabrielle, and is the NZ$22.3m segment result a sustainable run rate?
- Is there a dividend declared for HY24? The extraction records no declared dividend component, so payout posture alongside rising leverage is unclear.
- What is the covenant headroom on the expanded NZ$121.8m borrowing facility at 1.33x leverage?
This briefing cannot assess management's forward earnings capacity or return expectations from the capex programme because no guidance, target, or capex-purpose disclosure was supplied.
Key metrics
| Metric | HY24 | HY23 | Change |
|---|---|---|---|
| Revenue | $318.1m | $309.4m | +2.8% ↑ |
| EBITDA | $61.5m | $30.5m | +101.7% ↑ |
| Net profit after tax | $28.1m | $3.9m | +622.5% ↑ |
| Net cash inflow from operating activities | −$2.6m | −$23.9m | +89.3% ↑ |
| Operating profit | $51.2m | $20.5m | +150.0% ↑ |
| Profit before tax | $48.8m | $18.3m | +166.7% ↑ |
| Total assets | $739.8m | $619.7m | +19.4% ↑ |
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| Global Proteins | $141.7m | $151.1m | $28.1m | -4.3pp |
| Horticulture | $134.5m | $122.6m | $22.3m | +2.7pp |
| Logistics | $40.8m | $35.2m | $2.9m | +1.5pp |
| Other | $1.1m | $0.5m | −$4.5m | +0.2pp |
Analytical metrics
| Metric | HY24 | HY23 | Context |
|---|---|---|---|
| PBT growth | +166.7% | — | — |
| Effective tax rate | 22.0% | 22.0% | — |
| OCF / EBITDA (cash conversion) | -4.2% | -78.4% | stable |
| FCF pre-lease | −$47.1m | −$28.7m | −$18.4m |
| FCF / NPAT | -167.2% | -736.6% | complementary conversion metric |
| Capex % revenue | 14.0% | 1.6% | — |
| Capex | $44.5m | −$4.8m | +$49.3m |
| Debtor days | 1.3 | 0.2 | +1.1 days |
| Inventory days | 22.9 | 27.5 | -4.6 days |
| Trade debtors | $2.3m | $0.3m | +$2.0m |
| Net debt | $81.9m | $29.8m | +$52.1m |
| Net debt / EBITDA | 1.33x | 0.98x | Weakening |
| Gross borrowings | $121.8m | $67.5m | +$54.2m |
| ROE (annualised) | 14.7% | 2.1% | Strengthening |
| HY23 share of FY23 revenue | 54.7% | — | Other half was 45.3% |
| HY23 share of FY23 EBITDA | 56.8% | — | Other half was 43.2% |
| HY23 share of FY23 NPAT | 74.4% | — | Other half was 25.6% |
| Profit from continuing operations | $38.1m | $14.3m | +$23.8m |
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.